As an example, novel and more expensive glucose-lowering drugs such as GLP-1 RAs, DPP-4 inhibitors and SGLT2 inhibitors are less often prescribed in type 2 diabetes patients with statutory compared with patients with private health insurance [15]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.